Telaah Potensi Fibrosis Paru pada Penyintas Infeksi COVID-19 Secara Bioinformatik dengan Pensejajaran Sekuen Gen Pengkode Protein Spike Sars-Cov-2 dan Sars-Cov
DOI:
https://doi.org/10.29313/bcsp.v3i2.7720Keywords:
SARS-CoV-2, SARS-CoV, Spike Protein, Receptor Binding Domain (RBD), Pulmonary FibrosisAbstract
Abstract. SARS-CoV-2 is a novel virus that causes Coronavirus Disease 2019 (COVID-19). Compared to the SARS-CoV, SARS-CoV-2 has similarities in the total length of the spike protein, which consists of 1273 amino acids. The aim of this research is to compare the similarities or differences in the gene sequences encoding the S protein of SARS-CoV-2 and SARS-CoV, particularly in the RBD region, and to analyze the potential of pulmonary fibrosis in COVID-19 survivors based on the bioinformatics sequence alignment of the Spike protein gene sequences of SARS-CoV-2 and SARS-CoV. The research methodology employed is a bioinformatics study, starting with the retrieval of the gene sequences encoding the S protein of SARS-CoV-2 and SARS-CoV from the National Center for Biotechnology Information (NCBI) database. The sequences of both viruses are aligned using the Clustal Omega to compare the gene sequence encoding the S protein of SARS-CoV-2 to the gene encoding S protein in SARS-CoV. The base sequences that was is the RBD region. The sequence alignment of the base sequences encoding the S protein reveals differences in the DNA sequence in the region surrounding the RBD, specifically at positions 319-541. These differences in the sequence alignment of the gene sequences encoding the S protein between SARS-CoV-2 and SARS-CoV pose a risk for the occurrence of pulmonary fibrosis in COVID-19 survivors due to significant genetic variations between the two viruses.
Abstrak. SARS-CoV-2 merupakan jenis virus baru penyebab penyakit Coronavirus Disease 2019 (COVID-19). SARS-CoV-2 dibandingkan dengan SARS-CoV karena memiliki kemiripan dengan panjang total protein spike pada SARS-CoV-2 adalah 1273 asam amino. Tujuan penelitian ini adalah untuk membandingkan kesamaan atau perbedaan sekuen gen pengkode protein S SARS-CoV-2 dan SARS-CoV pada bagian RBD serta menganalisis potensi fibrosis paru pada penyintas infeksi COVID-19 berdasarkan pensejajaran sekuen gen protein Spike SARS-CoV-2 dan SARS-CoV secara bioinformatik. Metode yang digunakan dalam penelitian ini adalah studi bioinformatik, diawali dengan pencarian urutan gen pengkode protein S SARS-CoV-2 dan SARS-CoV dari laman National Center for Biotechnology Information (NCBI). Dilanjutkan dengan pensejajaran kedua virus tersebut menggunakan Clustal Omega untuk membandingkan urutan gen pengkode protein S SARS-CoV-2 dengan gen yang mengodekan protein S pada SARS-CoV. Urutan basa yang dianalisis adalah daerah RBD. Pensejajaran urutan basa pengkode protein S menunjukan adanya perbedaan urutan DNA pada daerah sekitar RBD yaitu pada posisi 319-541. Perbedaan hasil pensejajaran sekuen DNA protein S dari SARS-CoV-2 dan SARS-CoV tersebut memiliki indikasi efek yang berbeda pada penyintas infeksi COVID-19 karena adanya variasi genetik yang signifikan antara kedua virus tersebut.
References
[2] Lopez-Leon, S. et al "More Than 50 Long-Term Effects ff COVID-19: A Systematic Review and Meta-Analysis," Scientific Reports, 11(1), pp. 1–14. Available at: https://doi.org/10.1038/s41598-021-95565-8, 2021.
[3] Bungaro, M., Passiglia, F. and Scagliotti, G. V, "COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery," Biomedicines, 10(4). Available at: https://doi.org/10.3390/biomedicines10040776, 2022.
[4] Buana, I. and Harahap, D.A, "Asbestos, Radon Dan Polusi Udara Sebagai Faktor Resiko Kanker Paru Pada Perempuan Bukan Perokok," AVERROUS: Jurnal Kedokteran dan Kesehatan Malikussaleh, 8(1), p. 1. Available at: https://doi.org/10.29103/averrous.v8i1.7088, 2022.
[5] WHO, "COVID-19 Weekly Epidemiological Update," World Health Organization, (58), pp. 1–23. Available at: https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update, 2022.
[6] Zheng, J, "SARS-Cov-2: An Emerging Coronavirus That Causes A Global Threat," International Journal of Biological Sciences, 16(10), pp. 1678–1685. Available at: https://doi.org/10.7150/ijbs.45053, 2020.
[7] Petrosillo, N. et al, "COVID-19, SARS And MERS: Are They Closely Related," (January), 2020.
[8] Zhu, Z. et al, "From SARS And MERS To COVID-19: A Brief Summary And Comparison Of Severe Acute Respiratory Infections Caused By Three Highly Pathogenic Human Coronaviruses," Respiratory Research, 21(1), pp. 1–14. Available at: https://doi.org/10.1186/s12931-020-01479-w, 2020.
[9] Xie, Y. et al, "Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2," Frontiers in Molecular Biosciences, 7(December), pp. 1–14. Available at: https://doi.org/10.3389/fmolb.2020.591873, 2020.
[10] Huang, Y. et al, "Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19," Acta Pharmacologica Sinica, 41(9), pp. 1141–1149. Available at: https://doi.org/10.1038/s41401-020-0485-4, 2020.
[11] Tai, W. et al, "Characterization Of The Receptor-Binding Domain (RBD) Of 2019 Novel Coronavirus: Implication For Development Of RBD Protein As A Viral Attachment Inhibitor And Vaccine. Cellular and Molecular Immunology," 17(6), pp. 613–620. Available at: https://doi.org/10.1038/s41423-020-0400-4, 2020.
[12] Borkotoky, S., Dey, D. and Hazarika, Z, "Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective," Molecular Biology Reports, 50(3), pp. 2713–2721. Available at: https://doi.org/10.1007/s11033-022-08193-4, 2022.
[13] Guarneri, V. et al, "Epidemiology And Clinical Course Of Severe Acute Respiratory Syndrome Coronavirus 2 Infection In Cancer Patients In The Veneto Oncology Network: The Rete Oncologica Veneta Covid 19 Study. (January), 2021.
[14] Huang, W.J. and Tang, X.X, "Virus Infection Induced Pulmonary Fibrosis’, Journal Of Translational Medicine," 19(1), pp. 1–15. Available at: https://doi.org/10.1186/s12967-021-03159-9, 2021.
[15] Samet, J.M, "Does Pulmonary Fibrosis Increase Lung Cancer Risk," American Journal of Respiratory and Critical Care Medicine, 161(1), pp. 1–2. Available at: https://doi.org/10.1164/ajrccm.161.1.ed14-99, 2000.
[16] Venkataraman, T. and Frieman, M.B, "The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis," (January), 2020.
[17] Shirbhate, E. et al, "Understanding The Role Of ACE-2 Receptor In Pathogenesis Of COVID-19 Disease: A Potential Approach For Therapeutic Intervention," Pharmacological Reports, 73(6), pp. 1539–1550. Available at: https://doi.org/10.1007/s43440-021-00303-6, 2021.
[18] Ojo, A.S. et al, "Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies," Pulmonary Medicine, 2020. Available at: https://doi.org/10.1155/2020/6175964, 2020.
[19] Antar, S.A. et al, "Fibrosis: Types, Effects, Markers, Mechanisms for Disease Progression, and Its Relation with Oxidative Stress, Immunity, and Inflammation," International Journal of Molecular Sciences, 24(4). Available at: https://doi.org/10.3390/ijms24044004, 2023.
[20] Alhmoud, J.F. et al, "DNA Damage / Repair Management in Cancers, 2020.
[21] Giordano, D. et al, "Structural Dissection Of Viral Spike‐Protein Binding Of Sars‐Cov‐2 And Sars‐Cov‐1 To The Human Angiotensin‐Converting Enzyme 2 (Ace2) As Cellular Receptor," Biomedicines, 9(8), pp. 1–13. Available at: https://doi.org/10.3390/biomedicines9081038, 2021.
[22] Zhang, Q. et al, "Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy’, Signal Transduction and Targeted Therapy," 6(1). Available at: https://doi.org/10.1038/s41392-021-00653-w, 2021.
[23] Muhammad Ilham Hardian and Bertha Rusdi, "Studi Bioinformatika Mutasi Genetik pada Gen Pengkode Protein Spike dari Virus Sars-Cov-2 di Indonesia," Bandung Conference Series: Pharmacy, 1(1), pp. 18–23. Available at: https://doi.org/10.29313/bcsp.v1i1.89, 2021.
[24] Jungreis, I., Sealfon, R. and Kellis, M, "SARS-Cov-2 Gene Content And COVID-19 Mutation Impact By Comparing 44 Sarbecovirus Genomes," Nature Communications, 12(1), pp. 1–20. Available at: https://doi.org/10.1038/s41467-021-22905-7, 2021.
[25] Mustami, M.K. and Muthiadin, C, "Konsep Dasar Pewarisan Gen Pada Manusia Disertai Hasil Riset dan Analisis Resiko Mendel," Alauddin University Press. Available at: http://repositori.uin-alauddin.ac.id/id/eprint/21091, 2021.
[26] Shen, H. et al, "The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs," Frontiers in Pharmacology, 12(January), pp. 1–15. Available at: https://doi.org/10.3389/fphar.2021.805535, 2022.
[27] Naqvi, A.A.T. et al, "Insights Into SARS-Cov-2 Genome, Structure, Evolution, Pathogenesis And Therapies: Structural Genomics Approach," BBA - Molecular Basis of Disease, (January), pp. 1–17, 2020.
[28] Lukassen, S. et al, "SARS ‐Cov‐2 Receptor ACE 2 And TMPRSS 2 Are Primarily Expressed In Bronchial Transient Secretory Cells," The EMBO Journal, 39(10), pp. 1–15. Available at: https://doi.org/10.15252/embj.20105114, 2020.
[29] Madala, S.K. et al, "MEK-ERK Pathway Modulation Ameliorates Pulmonary Fibrosis Associated With Epidermal Growth Factor Receptor Activation," American Journal of Respiratory Cell and Molecular Biology, 46(3), pp. 380–388. Available at: https://doi.org/10.1165/rcmb.2011-0237OC, 2012.
[30] Wicik, Z. et al, "ACE2 Interaction Networks In COVID-19: A Physiological Framework For Prediction Of Outcome In Patients With Cardiovascular Risk Factors," Journal of Clinical Medicine, 9(11), pp. 1–29. Available at: https://doi.org/10.3390/jcm9113743, 2020.
[31] Kaur, N. et al, "Genetic Comparison Among Various Coronavirus Strains For The Identification Of Potential Vaccine Targets Of SARS-Cov2. (January), 2020.
[32] Zhang, H. et al, "Angiotensin-Converting Enzyme 2 (ACE2) As A SARS-Cov-2 Receptor: Molecular Mechanisms And Potential Therapeutic Target," Intensive Care Medicine, 46(4), pp. 586–590. Available at: https://doi.org/10.1007/s00134-020-05985-9, 2020.
[33] Krissinel, E, "On The Relationship Between Sequence And Structure Similarities In Proteomics," Bioinformatics, 23(6), pp. 717–723. Available at: https://doi.org/10.1093/bioinformatics/btm006, 2007.
[34] Rosyid, A.N. et al, "Virulence of Mutated SARS-CoV-2 and Susceptibility of COVID-19 Patient: A Literature Review. Journal of Hunan University (Natural Sciences), 48(7), pp. 229–237, 2021.
[35] Tan, J. et al, "Transmission And Clinical Characteristics Of Asymptomatic Patients With SARS-Cov-2 Infection’, Future Virology. 15(6), pp. 373–380. Available at: https://doi.org/10.2217/fvl-2020-0087, 2020.
[36] Savin, I.A., Zenkova, M.A. and Sen’kova, A. V, "Pulmonary Fibrosis as a Result of Acute Lung Inflammation: Molecular Mechanisms, Relevant In Vivo Models, Prognostic and Therapeutic Approaches," International Journal of Molecular Sciences, 23(23). Available at: https://doi.org/10.3390/ijms232314959, 2022.
[37] Palakkott, A. et al, "The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor- Mediated Signaling," bioRxiv, pp. 1–11, 2022.
[38] Xu, G. et al, "SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation’, Cell Research," 31(12), pp. 1230–1243. Available at: https://doi.org/10.1038/s41422-021-00578-7, 2021.
[39] Barratt, S.L. et al, "Idiopathic pulmonary fibrosis (IPF): An overview," Journal of Clinical Medicine, 7(8), pp. 1–21. Available at: https://doi.org/10.3390/jcm7080201, 2018.
[40] Sievers, F. and Higgins, D.G, "Clustal Omega For Making Accurate Alignments Of Many Protein Sequences," Protein Science, 27(1), pp. 135–145. Available at: https://doi.org/10.1002/pro.3290, 2018.
[41] Mahdieh, N. and Rabbani, B, "An Overview Of Mutation Detection Methods In Genetic Disorders," Iranian Journal of Pediatrics, 23(4), pp. 375–388, 2013.
[42] Tzellos, S. and Farrell, P.J, "Epstein-Barr Virus Sequence Variation-Biology And Disease, Pathogens. 1(2), pp. 156–175. Available at: https://doi.org/10.3390/pathogens1020156, 2012.
[43] Ikawaty, R, "Dinamika Interaksi Reseptor ACE2 dan SARS-CoV-2 Terhadap Manifestasi Klinis COVID-19," KELUWIH: Jurnal Kesehatan dan Kedokteran, 1(2), pp. 70–76. Available at: https://doi.org/10.24123/kesdok.v1i2.2869, 2020.
[44] Mihiretie, H. et al, "Mutations Of SARS-Cov-2 Spike Protein: Implications On Immune Evasion And Vaccine-Induced Immunity, 2020.
[45] Wilson, M.S. and Wynn, T.A, "Pulmonary Fibrosis: Pathogenesis, Etiology And Regulation, Mucosal Immunology," 2(2), pp. 103–121. Available at: https://doi.org/10.1038/mi.2008.85, 2009.
